PEA, BCP, and DHA Composition for Endocannabinoid Tone
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current analgesics are inadequate in managing chronic pain, particularly in neuropathic conditions, and the endocannabinoid system's inefficiency due to aging and stress leads to increased inflammation and age-related discomfort, with cannabinoids like CBD being legally and research-wise restricted.
Innovation Solution
A composition comprising palmitoylethanolamide (PEA), beta-caryophyllene (BCP), and docosahexaenoic acid (DHA) is administered to enhance the endocannabinoid system's tone, providing synergistic anti-inflammatory and analgesic effects without relying on Cannabis-derived compounds.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional analgesics are used to manage chronic pain, then pain relief is provided, but the relief is only partial and the treatment is generally inadequate
Solution Approach 1:
The patent combines multiple active agents (cannabinoids, NSAIDs, and other analgesics) into a single synergistic formulation. This merging of different therapeutic mechanisms addresses the inadequacy of single-agent or simple combination therapies, providing more complete pain relief while reducing the need for multiple separate medications.
Solution Approach 2:
The invention creates a composite pharmaceutical formulation containing multiple active ingredients with different mechanisms of action. This composite approach allows the treatment to address various aspects of chronic pain simultaneously, improving overall treatment adequacy beyond what conventional single-agent therapies can achieve.
2Reliability
If cannabinoids like CBD are used for anti-inflammatory and analgesic effects, then superior efficacy is achieved versus NSAIDs, but legal restrictions and research limitations are imposed
Solution Approach 1:
The patent combines CBD with other anti-inflammatory agents including NSAIDs and novel compounds. This combination allows the formulation to maintain the superior anti-inflammatory efficacy of cannabinoids while distributing the therapeutic effect across multiple mechanisms, potentially reducing legal and research restrictions associated with high-dose cannabinoid use alone.
Solution Approach 2:
The formulation uses NSAIDs and other anti-inflammatory agents as intermediary compounds that can partially substitute for or work alongside cannabinoids. These intermediaries provide alternative pathways to achieve anti-inflammatory effects, reducing dependence on restricted substances while maintaining therapeutic efficacy.
3Reliability
If the endocannabinoid system becomes less efficient due to aging and stress, then homeostasis is compromised leading to increased inflammation, but no effective prophylactic treatment is available
Solution Approach 1:
The patent provides a prophylactic formulation that can be administered before age-related endocannabinoid decline fully manifests. By taking preliminary action to support endocannabinoid function and reduce inflammation early, the formulation prevents the development of chronic inflammatory conditions associated with aging and stress, rather than merely treating them after onset.
Solution Approach 2:
The formulation supports the body's own endocannabinoid system by providing precursors and compounds that enhance its natural function. Rather than completely replacing endocannabinoid activity with external substances, the treatment enables the body's self-regulatory mechanisms to maintain homeostasis more effectively despite aging and stress.
Data Source
AI summary
Compositions and methods for prophylactically sustaining and/or maintaining a robust endocannabinoid system in patients for modulating excess inflammatory response and inflammatory diseases over the mammalian lifespan to mitigate age-related discomfort. Specifically, a method of treating inflammatory and neuropathic pain in a mammal by administering a synergistic pharmaceutical daily dosage form comprising: palmitoylethanolamide (PEA), beta-caryophyllene (BCP) and docosahexaenoic acid (DHA).